Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease

Autor: Joe Kai, Ian C. K. Wong, Nadeem Qureshi, Chung-Wah Siu, Barbara Iyen, Joseph E Blais, Wallis C.Y. Lau, Ralph K. Akyea, Kenneth K.C. Man, Stephen Weng, Esther W. Chan
Přispěvatelé: Pizzi, Carmine
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Epidemiology
Disease
Cardiovascular Medicine
Biochemistry
Geographical locations
Medical Conditions
Medicine and Health Sciences
Multidisciplinary
Pharmaceutics
Hazard ratio
Area under the curve
Drugs
propensity
sub-optimal low-density lipoprotein cholesterol response
statins
cardiovascular disease

Middle Aged
Lipids
Cardiovascular Therapy
Cholesterol
Cardiovascular Diseases
Cohort
Cardiology
Medicine
Hong Kong
Female
Risk assessment
Research Article
medicine.medical_specialty
Statin
Asia
medicine.drug_class
Science
Lipoproteins
Risk Assessment
Drug Therapy
Internal medicine
medicine
Humans
cardiovascular diseases
Aged
Pharmacology
business.industry
Statins
Biology and Life Sciences
Proteins
Cholesterol
LDL

Cardiovascular Disease Risk
Confidence interval
United Kingdom
Medical Risk Factors
People and places
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Mace
Zdroj: PLoS ONE
PLoS ONE, Vol 16, Iss 12, p e0260839 (2021)
ISSN: 1932-6203
Popis: Background Variability in low-density lipoprotein cholesterol (LDL-C) response to statins is underappreciated. We characterised patients by their statin response (SR), baseline risk of cardiovascular disease (CVD) and 10-year CVD outcomes. Methods and results A multivariable model was developed using 183,213 United Kingdom (UK) patients without CVD to predict probability of sub-optimal SR, defined by guidelines as Conclusions Patients with sub-optimal response to statins experienced significantly more MACE, regardless of baseline CVD risk. To enhance cholesterol management for primary prevention, statin response should be considered alongside risk assessment.
Databáze: OpenAIRE